Literature DB >> 16538760

Living well with end stage renal disease: patients' narratives interrupted from a virtue perspective.

Wim Dekker1, Inez Uerz, Jean-Pierre Wils.   

Abstract

Over the last few decades there has been a revival of interest in virtue ethics, with the emphasis on the virtuous caregiver. This paper deals with the 'virtuous patient', specifically the patient with End Stage Renal Disease (ESRD). We believe that a virtue approach provides insights not available to current methods of studying coping styles and coping strategies. Data are derived from seven semi-structured in-depth interviews. The transcripts of the interviews were subjected to an Interpretative Phenomenological Analysis (IPA). The focus of the analysis was on 'living well with chronic illness.' It appears that the moral challenges faced by patients with ESRD are manifold. When they are invited to tell the story of their illness, they do not explicitly speak of virtues, but they often refer to moral qualities, and to attitudes that can be regarded as virtuous. We identify several such concepts in the narratives of patients with ESRD. We conclude that the Aristotelian model of virtue ethics is particularly descriptively (and possibly also normatively) relevant to the explanation of the life narratives and the moral challenges of patients with an ESRD.

Entities:  

Keywords:  Aristotle; Empirical Approach; Health Care and Public Health

Mesh:

Year:  2005        PMID: 16538760     DOI: 10.1007/s10677-005-8242-9

Source DB:  PubMed          Journal:  Ethical Theory Moral Pract        ISSN: 1386-2820


  2 in total

1.  Taking patient virtue seriously.

Authors:  J K Miles
Journal:  Theor Med Bioeth       Date:  2019-04

2.  Work of being an adult patient with chronic kidney disease: a systematic review of qualitative studies.

Authors:  Javier Roberti; Amanda Cummings; Michelle Myall; Jonathan Harvey; Kate Lippiett; Katherine Hunt; Federico Cicora; Juan Pedro Alonso; Carl R May
Journal:  BMJ Open       Date:  2018-09-04       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.